

# ovarian canceraction




Monica




Erica



Rita



Tina




Sandra



Mary



Jessica



Ore



Daisy



Vicke




Leonie



Rebecca



Niralee



Jess



Lynsey



Annual report  
**2015-16**

# Contents

<b>The picture today</b> .....	<b>3</b>
<b>The future</b> .....	<b>4</b>
<b>Our raison d'être</b> .....	<b>5</b>
<b>What's the problem?</b> .....	<b>6</b>
<b>What will we do about it?</b> .....	<b>7</b>
<b>Chair's report</b> .....	<b>8</b>
<b>Directors' report</b> .....	<b>10</b>
What we said we'd do in 2015/2016.....	11
Our top 10 proudest moments.....	13
In the last year, our supporters have.....	23
What we'll do in 2016/2017.....	24
The financial bit.....	26
Your donations this year.....	27
Financial review.....	28
Our structure, governance and management.....	29
Statement of Directors' responsibilities.....	30
<b>Auditors' report</b> .....	<b>31</b>
<b>Statement of financial activities</b> .....	<b>33</b>
<b>Balance Sheet as at 31 March 2016</b> .....	<b>34</b>
<b>Statement of Cash Flows for year ending 31 March 2016</b> .....	<b>35</b>
<b>Notes to the financial statements</b> .....	<b>36</b>
<b>The year in photos</b> .....	<b>45</b>
<b>Thank yous</b> .....	<b>46</b>
<b>The legal bit</b> .....	<b>47</b>

# The picture today: about ovarian cancer



In the UK, a woman dies from ovarian cancer every two hours.



It is the deadliest of all gynaecological cancers.



Globally 225,000 women are diagnosed with ovarian cancer each year. About 7,200 cases are diagnosed each year in the UK.



Women in the UK have a 1 in 52 risk of developing the disease.



Ovarian cancer has a very high rate of recurrence; the disease recurs in between 70% and 90% of cases compared with just 22% for breast cancer.



There are prevention strategies for women at increased risk of hereditary ovarian cancer



17% of women with ovarian cancer have a BRCA1/2 gene mutation



Survival rates for women with ovarian cancer in the UK lag behind those of other developed countries and are amongst the worst in Europe.



Early detection makes a big difference. Women diagnosed at stage 1 have a 90% survival rate compared to 19% at stage 3



Treatment options haven't progressed much in more than 30 years

# The future



The average length of survival for women with ovarian cancer has increased significantly in the last 10 years; the age of the **'super survivor'** seems more and more attainable.

The world of ovarian cancer research is at a crucial tipping point and there is a palpable feeling in the field that we are on the edge of breakthrough. For this to happen, investment in research, worldwide scientific collaboration and raising awareness all remain more crucial than ever.

**We believe in a future in which no woman dies of ovarian cancer.**

# Our raison d'être

We exist to stop women dying from ovarian cancer before their time.



## What do we do to save lives?



### We find the innovators

We hunt for the best researchers out there and we bring them together to share ideas. We foster talent.



### We fund the innovators

We only fund research that makes a real difference to the lives of women.



### We shout


We spread the word as far as wide as we can. We're frustrated that, still, not enough women and healthcare providers know the risk factors, symptoms and treatment options.



### We change

We campaign to make a difference. We believe the future can be different and we won't stop until it is.

# What's the problem?



The problem is that the science is **slow**. Progress needs to be **sped up**, to stop women dying




The problem is that there isn't **enough money**. Ovarian cancer research is **vastly underfunded**



The problem is that not all women have **access** to the **best surgery**



The problem is that women with ovarian cancer deserve **better information** about their treatment. They deserve the right to make **informed choices**



The problem is that, despite being entitled to it, too many women with ovarian cancer are not being offered **genetic testing** at the point of diagnosis



The problem is that ovarian cancer doesn't get as much **attention** as other cancers and symptoms **awareness is poor**




The problem is that **nobody's listening**. Women with ovarian cancer **deserve to be heard**

# What will we do about it?



We will keep **funding** the research that matters. Ovarian cancer should **never** be a death sentence.




We will **speed up** scientific breakthroughs by fostering strong **international co-operation** and collaboration



We will **keep fighting** for the best surgery for women with ovarian cancer. We believe **surgery is critical** in determining survival



We will help women make **empowered choices** and continue to fight for a **personalised approach** to treatment. We don't believe that one size fits all.



We won't give up until all women are offered **genetic testing** at point of diagnosis



We will keep **spreading awareness** far and wide. Every woman should know the **symptoms** of ovarian cancer



We will **make the world listen**, and keep demanding that all UK women get the **best quality treatment**

# Chair's report

This is Ovarian Cancer Action's tenth anniversary year; it's ten years since we began funding scientific research at our own research centre. We've grown into a thriving charity that has invested millions of pounds into ovarian cancer research in the UK, and we have more than 50 scientists at our centre. Our job is to stop women dying from ovarian cancer before their time and I am inspired by the progress and achievements that have been made.

There is still much more to be done. We are still frustrated by the lack of funding, frustrated at how long science takes to come to the aid of real people and how long it takes to change laws or practice around patient care. A woman diagnosed with ovarian cancer today has a 46% chance of being alive in 5 years' time. Survival rates have improved but we can still do much better. A new observation is that a subgroup of women are surviving longer, we call these women super-survivors. We must look after their needs and scientifically work out why they are living longer.

Today, we are looking forward to the next ten years of funding research. Research is one of the many things we do and the truly inspirational part of our portfolio is the HHMT meeting. It's important to us because it sets our research strategy, as well as prioritising ovarian cancer research around the world. Our scientific committee handpick 40 top clinicians and researchers to debate the smartest way forward. Despite Michael Gove saying 'we have had enough of experts', we relied heavily on international expertise to shape a 'Roadmap' on

future directions in research. The priorities were published in a collaborative paper in October 2015 in Nature Reviews Cancer.

Across the UK, our scientists drive research into the clinic where it can best benefit patients. From Edinburgh and Glasgow to Oxford and London, the Ovarian Cancer Action research team tackle critical questions such as why, over time, does chemotherapy stop working? In this year alone more than £700,000 was invested at our Ovarian Cancer Action Research Centre at Imperial College, where basic scientists and clinician scientists work side by side.

In tackling ovarian cancer we know the importance of women and families sharing their experiences. One true story can bring to life the real dilemmas of symptoms, surgery and treatment and raise awareness of the disease. During Ovarian Cancer Awareness Month in March 2016 we reached millions of people with messages about ovarian cancer.

We continue to campaign for all women with ovarian cancer to receive a BRCA gene test; we were delighted to see a change in clinical commissioning policy in July 2015 but now we must push oncologists and GPs to follow the guidelines and understand the shared hereditary risk of breast and ovarian cancer. Our job, as we go forward, is to ensure implementation and we'll continue to lobby the government until this becomes common practice.

*cont >*

BRCA testing provides an unprecedented opportunity to prevent 17% of ovarian cancer. We are fighting for better BRCA provision. We were delighted to be recipients of a major £300,000 government grant from the Treasury to run a BRCA cancer prevention project.

Our flagship campaign #WalkInHerName has gone from strength to strength and is now in its second year; with more than 800 walkers covering 11,560 miles and raising £40,000.

These are just some of the things we've achieved over the last year. We are defined by our actions, not our words. We are humbled and inspired by our supporters.

None of this could be achieved without the inspiring bravery, dedication and commitment of our incredible supporters. My thanks go to the donors, funders, researchers, Ovarian Cancer Action Voices and scientific advisors, as well as Katherine Taylor and the passionate office team. They give me faith that we can create change as we plan for the next ten years.



**Allyson Kaye, MBE**  
**Chair of the Board**  
**Date: 5th September 2016**



# Directors' report

## Report of the directors

The directors of the charity for the purpose of the Companies Act, are pleased to present their report and accounts for the year ended 31 March 2016 which are also prepared to meet the requirements for a directors' report and accounts for Companies Act purpose.

The financial statements comply with the Charities Act 2011, the Companies Act 2006, the Memorandum and Articles Of Association, and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015).

## Transition to FRS 102

The date of transition to FRS 102 was 1 April 2014. The reported financial position and financial performance for the previous period are not affected by the transition to FRS 102.

## Public benefit

The Charities Act 2011 requires all charities to meet the legal requirement that its aims are for

the public benefit. The Charity Commission in its Charities and Public Benefit guidance states that there are two key principles to be met in order to show that an organisation's aims are for the public benefit: firstly, there must be an identifiable benefit or benefits and secondly, that the benefit must be to the public or a section of the public. The directors consider that they have complied with Section 17 of the Charities Act 2011 including the guidance 'public benefit: running a charity (PB2)'.

## Pay policy for staff

The Chief Executive and the senior management team including the Public Affairs and Operations Manager, Senior Fundraising Manager, Research Fundraising Manager and Head of Communications comprise the key management personnel of the charity in charge of directing and controlling, running and operating the charity on a day to day basis.

All Directors give of their time freely and no Directors received remuneration in the year.

The pay of senior staff is reviewed annually and is normally increased in accordance with average earnings.

# What we said we'd do in 2015/2016

<b>RESEARCH</b>	
Work with the Ovarian Cancer Action Research Centre to drive the research programme and implement the proposals of the mid Quinquennial review.	
Work with the Ovarian Cancer Action Research Centre to explore opportunities in surgery and genetics.	
Follow up the HHMT Forum with a Nature Reviews Cancer paper and lay summary to inform thinking in ovarian cancer research.	
Work with BriTROC to explore participation in the 100,000 genome project.	
Communicate the latest science in the field of ovarian cancer as widely as possible.	
Continue to position Ovarian Cancer Action as the leading scientific research charity for ovarian cancer.	
<b>AWARENESS</b>	
Campaign around hereditary and genetic disease, leading to change in access to BRCA gene testing for women with ovarian cancer.	
Participate in Ovarian Cancer Awareness Month	
Launch a Regional Awareness Officer programme.	
Communicate effectively with GPs and nurses to support early diagnosis.	
Launch a symptoms app to support early diagnosis.	
Support younger women with information about ovarian cancer.	
Continue to find innovative ways to communicate the charity's messages and work.	

# What we said we'd do in 2015/2016

<b>VOICES</b>	
Strengthen relationship with our active Voices and extend recruitment.	
Grow an engagement programme with our Voices, and continue to involve them in the charity's work.	
<b>GOVERNANCE</b>	
Improve database and IT to support fundraising team.	
Deliver pension scheme to employees.	
Refresh board membership with additional trustees.	
Streamline financial processes.	
Continue to provide effective HR support.	

## Our top 10 proudest moments

# 1 | That time we were published

Ovarian cancer research will only be accelerated if ideas are shared and the greatest minds work together. That's why, every few years, we organise an International Forum, HHMT.

HHMT sees the world's leading ovarian cancer scientists come together to share ideas, ask and answer questions, debate, and agree on a roadmap for the future of ovarian cancer research.

After the 2015 HHMT, these priorities were published in Nature Reviews Cancer. From better prevention to cracking the key to platinum resistance, the paper Rethinking Ovarian Cancer II: Reducing Mortality from High-Grade Serous Ovarian Cancer outlines crucial areas of focus for future research.

“ If ovarian cancer is going to be cured it will be largely by the people in this room. ”

– Dr Karen Lu, Attendee



## Our top 10 proudest moments

# 2 | That time we waited at the finish line

This year thousands of women clambered into their cycling gear and rode their bikes through the night to fundraise.

Women V Cancer's Ride the Night is an annual cycle ride to raise funds for three women's charities – and Ovarian Cancer Action is lucky to be one of them.

We were delighted to be at the finish line, cheering on the inspirational woman that took on the gruelling 100km ride.



**Distance: 100km**



**Participants: 1,644 women**



**Start time: 9pm**



**Finish Time: 7.30am**



**Route: Windsor race course, through central London and back again.**



**Total raised:  
Circa £1million  
We received: £215,515**




## Our top 10 proudest moments

# 3 | That time we all worked together

80% of women who get ovarian cancer are over the age of fifty. But that leaves one in five who are younger. Dealing with ovarian cancer as a young woman has a unique set of issues to contend with.

And that's why we were delighted to partner with three other woman's charities to create a specialist ovarian cancer guide for younger women.

The guide contains everything you need to know about treatment, relationships, fertility and facing an early menopause.



## Our top 10 proudest moments

# 4 | That time we walked 11,560 miles

Our flagship campaign, Walk in Her Name, goes from strength to strength. This year, hundreds of supporters around the country donned their walking boots, wellies and wet-weather gear and set off in their communities to raise funds in the name of a woman they love.

Mandy Lording organised a walk for 50 people through Woburn in memory of her sister Heidi. She said: "This event was perfect, Heidi was a very sociable person with a large network of friends, this was the perfect opportunity to get her friends and family together and honour the person everyone loved and missed."

A huge thank you to our wonderful supporters. With your help we can walk, step by step, towards a better future for women with ovarian cancer.



**43 walks completed**



**800 participants**



**11,560 miles walked**

That's more than 23 million steps!



**Hit our £40,000 target**

**£57,174.77 raised**

(£17,536 donated to us after the year end)



## Our top 10 proudest moments

# 5 | That time we helped Claudia

At the Ovarian Cancer Action Research Centre all our research goes 'from bench to bedside'. That's a fancy way of saying that we only fund research which translates from the lab to clinical trials. In even simpler terms; it has real benefits for women with ovarian cancer. Not just in 10 years' time, but now.

Clinical trials help doctors and medical researchers understand more about a disease and how to treat it.

There are trials looking at drugs and treatments, but also those that look beyond treatment to consider psychological effects.

Between 2013 and 2016 we ran a clinical trial, OvPsych2, looking at the psychological health of women who'd been treated for ovarian cancer.

Claudia, who took part in OvPsych2, says:

*"Ovarian cancer is a horrible, sneaky cancer. Because it is sneaky, many women die. Because it is sneaky, most women are petrified of it. I was. It was my 'I absolutely would never want to have that one' cancer.*

*"But we can beat it. By studying it we can make it less sneaky, less deadly. By laying bare its secrets and sniffing it out, we can improve the future for other women. And that's why I took part in OvPsych2."*

**“** I found the sessions immensely helpful and I met some lovely people in the same 'cancer boat'. It helped me to be happy, to enjoy my life. **”**



## Our top 10 proudest moments

# 6 | That time we went to Wales

Wales gets a raw deal when it comes to ovarian cancer.

But it's about time the NHS in Wales stood up and paid attention to the stats.

1, 3 and 5 year rates in Wales is the lowest in the UK.

Ovarian cancer incidence rates in Wales are the highest in the UK.

Geographical variation in access to drugs means that many ovarian cancer patients in Wales are forced to relocate to England in order to access treatments

Access to genetic testing is much more difficult despite Wales following the same guidelines as England.

Wales has consistently missed its cancer waiting times year on year since 2007.

And that's why we're delighted to have welcomed Alicia to the team as Wales Regional Officer.

Dedicated to raising as much awareness as possible, Alicia joined us in April 2016 and is ready and raring to stand up and make a noise for all Welsh women affected by ovarian cancer.




## Our top 10 proudest moments

# 7 | That time we got appy

The symptoms of ovarian cancer are nebulous and are often mistaken for other conditions. We advise women who are worried about ovarian cancer to keep a symptoms diary, to track their symptoms and to help their GP rule out ovarian cancer.

We created a paper symptoms diary years ago but are delighted to have got ahead of the game and, this year, we launched our very own symptoms diary app.



## Our top 10 proudest moments

# 8 | That time we made a breakthrough

Ovarian cancer can be difficult to diagnose because it grows virtually unseen and symptoms can be hard to detect. And, sadly, later diagnosis is linked to worse outcomes.

One of our research projects, led by Professor Ahmed Ahmed, has been looking for a way to detect the disease earlier as a means of saving more lives.

And we're beside ourselves that, this year, he and his team at Oxford University have made huge strides towards a possible way to detect ovarian cancer before it even occurs.

Professor Ahmed and his team found that levels of a protein called SOX2 are much higher in the fallopian tubes of people with ovarian cancer and those genetically predisposed to the disease.

Eventually, the breakthrough could lead to early screening for the disease in a similar vein to a cervical smear test.

There is still a lot to be done because SOX2 isn't easy to detect. But a test could not only help detect cancers early, in some cases would enable us to detect a tumour before it even becomes cancerous.

## Our top 10 proudest moments

# 9 | That time we were on...

**BBC**  
RADIO



### ...not once, but twice!

Last year was very good for media coverage. With 750 mentions across the National, Regional and specialist press, it's hard to pick a highlight.

Right up there, though, is when we were on Women's Hour on BBC Radio 4. We spoke about the impact of Angelina Jolie on the awareness of BRCA gene mutations.

Our Chief Executive did such a good job the first time 'round, that they invited her back again! This time she took one of our supporters, Deana, and the impact they made between them was impressive.

- Page views on our website increased from 1,956 on previous day to 5,717 on the day the story aired.

**That's an increase of 192%!**

- 285 used our BRCA Risk Tool on the day it aired vs an average of 14 per day
- Woman's Hour has an audience of more than 3.5 million. That's a lot of people to reach with our messages!



- **Angelina Jolie is a famous carrier of a BRCA gene mutation. She has had surgery to reduce her chances of getting cancer.**
- **Carrying a BRCA1/2 gene mutation gives a woman an 80% lifetime chance of developing breast cancer and a 35%-60% chance of developing ovarian cancer**
- **BRCA1/2 gene mutations can be passed on through either your mother or your father**
- **If your mother or father has a BRCA1/2 gene mutation, you have a 50% chance of having one too**
- **People from Ashkenazi Jewish, Icelandic, Norwegian, Dutch, Pakistani and Polish populations are more likely to have a BRCA 1/2 mutation**
- **Measures can be taken to prevent cancer if a BRCA1/2 gene mutation is identified**

## Our top 10 proudest moments

# 10 | That time we 'Acted on BRCA'

In November 2015 we were joined by more than 100 supporters to launch our latest campaign – 'Acting on BRCA: the opportunity for a cancer prevention strategy'.

Cancers associated with a BRCA1/2 gene mutation have high mortality and can be hard to detect.

We believe that testing for BRCA1/2 gene mutations provides a significant opportunity for preventing future cases of cancer, through options including risk-reducing surgery and increased surveillance.


**We believe that by Acting on BRCA some 1,000 cases of ovarian cancer could be prevented each year in the UK.**

Luckily the government agreed. In March 2016 we were named as one of the beneficiaries of the 'Tampon Tax' revenue in the budget. This £300,000 grant will be invested in funding research into hereditary cancer at the Ovarian Cancer Action Research Centre, and in funding a Cancer Prevention Officer here at Ovarian Cancer Action to help spread the word.

Watch this space!



# In the last year, our supporters have



# What we'll do in 2016/2017

## RESEARCH

Deliver up to date research strategy to prepare OCA for the next three years of funding scientific research.

Work with the Ovarian Cancer Action Research Centre to prepare for the centre's second quinquennial review.

Support genetic testing pilot project in partnership with primary care.

Explore research into new technologies and partnerships with Imperial College.

Plan 14<sup>th</sup> HHMT International Forum on Ovarian Cancer.

Communicate the latest science in the field of ovarian cancer as widely as possible.

Refresh Scientific Advisory Board membership.

# What we'll do in 2016/2017

## AWARENESS

Continue to campaign about hereditary ovarian cancer, extending information and reach through a cancer prevention programme.

Extend ovarian cancer awareness in Wales through a regional programme.

Update website to ensure information is accurate and accessible.

Run pilot programme to explore nurses training other healthcare providers as part of overall GP/healthcare provider engagement.

Campaign with memorable messages during Ovarian Cancer Awareness Month.

Continue to find innovative ways to communicate the charity's messages and work.

## VOICES

Continue to improve information for Voices to encourage participation and grow numbers of active Voices.

Engage Voices through training, focus groups and thanking events.

## GOVERNANCE

Progress three year strategic plan to accompany research strategy.

Continue to refresh board membership with additional trustees.


# The financial bit



**Income: £1,785,527 | Expenditure: £1,448,534**

(That's an increase of 6% from last year!)

For every pound we spend...



# Your donations this year have helped fund...

## A busy team of experts

**201**

Researchers



They've recruited...



**413**  
patients

into trials,  
publishing

**31**  
papers



on their research in the last year.

## Spreading the word about ovarian cancer

Our information stands have reached...



**8,000**  
people

and we've had face-to-face interactions with over

**1,000**  
of them.



Our symptom posters have been posted on toilet doors around the country helping...



**7.6**  
million women

to spot signs of ovarian cancer.

We've collaborated with GPs and nurses in...



**48**  
health centres

across the UK, reaching around



**100,000**  
patients

Our conversations with over...



**700**  
health professionals

have helped to reach more than



**1 million**  
patients across the country.

We've distributed over...



**20,000** information leaflets, posters and symptom diaries.

We've engaged with



**19** MPs

to put ovarian cancer and BRCA on the parliamentary agenda in the last year.

## Our good governance promise

At Ovarian Cancer Action we promise to ensure our processes and operations are efficient and scaled appropriately for a small organisation. In English, this means we'll always keep our fundraising and running costs as low as possible so we can use your donations to fund scientific research, raise awareness and to beat this disease once and for all.

## Financial Review

The Directors report that the charity's incoming resources amounted to £1,785,527 an increase from £1,684,829 in the previous year.

The Directors would like to thank all those volunteers and donors - corporate, trusts and foundations, as well as individual donors who have supported the charity in increasing numbers over the past year and upon whom we are dependent.

Income includes legacies of £206,829 (2015 – £160,866).

Total expenditure on charitable activities (research, awareness raising and giving a voice) and expenditure on raising funds amounted to £1,104,541 (2015 – £1,214,552) and £343,993 (2015 – £343,475) respectively. The Directors were delighted to be able to make additional research grants totalling £710,000 to fund work at the Ovarian Cancer Action Research Centre.

As a result of these activities, the charity has a surplus of £336,993 (2015 – £126,802).

### Principal Funding Sources

A detailed breakdown of funding sources is given in Note 3 to the Financial Statements.

### Reserves Policy

In accordance with Charity Commission guidance, free reserves are uncommitted reserves freely available which exclude restricted and designated funds and amounts invested in tangible fixed assets. Designated funds arise when the Directors set aside unrestricted funds for specific purposes. Restricted funds arise when conditions are imposed by the donor, or by the specific terms of appeal, and can only be spent on the activities specified.

Ovarian Cancer Action relies almost entirely on voluntary income, which is subject to fluctuation. In order to ensure the continuance of the charity's day-to-day activities, the Directors have established a policy to hold free reserves equivalent to at least three months' expenditure excluding grants and expenditure from restricted funds planned for the year ahead.

At 31 March 2016 the Charity held total reserves of £1,924,219 (2015 - £1,587,226). These were split into restricted, designated and general funds.

At 31 March 2016, restricted funds amounted to £514,000 (2015 – £253,334). At 31 March 2016, designated funds amounted to £1,210,000 (2015 – £1,210,000); these were funds set aside to fund future research expenditure. The amount of the general fund available as a reserve against fluctuating income, at 31 March 2016, was £200,218 (2015 – £123,890). This amounted to three months unrestricted non grant expenditure and thus complied with the reserves policy established by the Board.

The breakdown of the reserves between restricted, designated and general funds is shown in Note 15 to the Financial Statements.

## Our structure, governance and management

### Legal entity

Ovarian Cancer Action is a company limited by guarantee registered as a Company in England and Wales on 24 March 2005, and as a registered Charity in England and Wales on 27 May 2005. On 11 October 2012 the Charitable Company registered as a Scottish Charity at the office of the Scottish Charity Regulator. Its governing document is the Memorandum and Articles of Association.

### Organisational structure

Ovarian Cancer Action is governed by a Board of Directors whose responsibilities include setting the strategic direction and goals of the Charity and providing effective governance. The Board meets four times a year. The Chief Executive is supported by a small team of staff, with a fulltime equivalent of 12 employees.

### Role and contribution of volunteers

Nicholas Kaye FCA of AEL Partners LLP provides financial assistance on a pro bono basis. Ovarian Cancer Action is indebted to all those supporters who play a vital role in raising awareness of ovarian cancer in their communities, in the local and national media, and by raising funds for our work.

### Appointment, induction and training of Directors

New Directors are appointed by the Board of Directors and must be re-appointed by the members at the first annual general meeting following their appointment to be able to continue to serve. All Directors must be members of Ovarian Cancer Action. Each new Director attends an induction session with the Chief Executive to confirm the role, responsibilities and expectations of Directors and highlight current governance and strategic issues. The session includes an overall view of the history of the organisation, current activities and future plans.

### Grant-making policies

Ovarian Cancer Action invites applications for research funding from within and outside the Ovarian Cancer Action Research Centre. All grant applications are subject to rigorous peer review by the Scientific Advisory Board (SAB), which is an international, independent group of ovarian cancer research specialists chaired by Dr. Robert C. Bast Jr, Vice-President of Translational Medicine at the University of Texas MD Anderson Cancer Center.

### Relationships with other charities

The Board of Directors actively seeks to collaborate with other charities where this will accelerate improvements in survival. Ovarian Cancer Action played a leading role in the establishment of Ovarian Cancer Awareness Month (OCAM) in the UK. Membership is held at Cancer 52, The Cancer Campaign Group, the Association of Medical Research Charities and the Fundraising Standard Board. Ovarian Cancer Action has partnered with male cancer charity Orchid for future fundraising opportunities.

### Risk management

The Board of Directors monitors the principal business and control risks to the charity and has completed a formal risk assessment.

### Directors

The Board of Directors during the year and at the date of signing this report are listed on page 47, as are the company and charity numbers of Ovarian Cancer Action.

## Statement of Directors' responsibilities

The Directors are responsible for preparing the Directors' Annual Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Directors to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the incoming resource and application of resources, including the income and expenditure, of the charitable company for that period.

In preparing these financial statements, the Directors are required to:-

- Select suitable accounting policies and then apply them consistently;
- Observe the methods and principles in the Charities SORP;
- Make judgments and estimates that are reasonable and prudent;
- State whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- Prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The Directors are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and which enable them to ensure that the accounts comply with the Companies Act 2006, the Charities and Trustee Investment Act 2005 and the Charitable Accounts (Scotland) Regulations 2006 (as amended).

They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the Directors are aware:

- There is no relevant audit information of which the charitable company's auditor is unaware; and
- The Directors have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

The Directors are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

### Auditors

The auditors, Wilson Wright LLP, will be proposed for reappointment in accordance with Section 485 of the Companies Act 2006.

Signed on behalf of the Board



Allyson J. Kaye, MBE, Chair  
Chair, Board of Directors  
Date: 5 September 2016

## Independent Auditors' report to the trustees and members of Ovarian Cancer Action

We have audited the financial statements of Ovarian Cancer Action for the year ended 31 March 2016, which comprise the Statement of Financial Activities (including Income and Expenditure Account), the Balance Sheet, the Statement of Cash Flows and the related notes. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

This report is made exclusively to the members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006, and to the charity's directors as a body in accordance with Section 44(1) (c) of the Charities and Trustee Investment (Scotland) Act 2005 and Regulation 8 of the Charities Accounts (Scotland) Registrations 2006. Our audit work has been undertaken so that we might state to the members and the charity's directors those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity, its members as a body and its directors as a body, for our audit work, for this report, or for the opinions we have formed.

### Respective responsibilities of board of directors and auditors

As explained more fully in the Directors' Responsibilities Statement set out in the Directors' Report, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view.

We have been appointed as auditors under section 44 (1) (c) of the Charities and Trustee Investment (Scotland) Act 2005 and under the Companies Act 2006 and report in accordance with regulations made under those Acts.

Our responsibility is to audit and express an opinion on the financial statements in accordance with applicable law and International Standards on Auditing (UK and Ireland). Those standards require us to comply with the Auditing Practices Board's (APB's) Ethical Standards for Auditors.

### Scope of the audit of the financial statements

An audit involves obtaining evidence about the amounts and disclosures in the financial statements sufficient to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or error. This includes an assessment of: whether the accounting policies are appropriate to the charitable company's circumstances and have been consistently applied and adequately disclosed; the reasonableness of significant accounting estimates made by the trustees; and the overall presentation of the financial statements. In addition we read all the financial and non-financial information in the Chair's and Directors' Reports to identify material inconsistencies with the audited financial statements and to identify information that is apparently materially incorrect based on, or materially inconsistent with, the knowledge acquired by us in the course of performing the audit. If we become aware of any apparent material misstatements or inconsistencies, we consider the implications for our report.

## Opinion on financial statements

In our opinion the financial statements

- Give a true and fair view of the state of the charitable company's affairs as at 31 March 2016 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006, reg.8 (as amended).

- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

**Kevin Maddison FCCA Senior Statutory Auditor for and on behalf of Wilson Wright LLP Chartered Accountants and Statutory Auditors**

Thavies Inn House,  
3-4 Holborn Circus,  
London  
EC1N 2HA

Date: 5 September 2016

## Opinion on other matter prescribed by the Companies Act 2006

In our opinion the information given in the Chair's and the Directors' Annual Report for the financial year for which the financial statements are prepared is consistent with the financial statements.

## Matters on which we are required to report by exception

We have nothing to report in respect of the following matters where the Companies Act 2006 and the Charities (Scotland) Regulations 2006 (as amended) requires us to report to you if, in our opinion:

- the charitable company has not kept proper and adequate accounting records or returns adequate for our audit have not been received from branches not visited by us;
- the financial statements are not in agreement with the accounting records and returns;

## Statement of Financial Activities (including Income and Expenditure account) for the year ended 31 March 2016

	Notes	Unrestricted Funds £	Restricted Funds £	Total 2016 £	Total 2015 £
<b>Income</b>					
Donations and legacies	3	1,350,315	427,000	1,777,315	1,680,582
Investment income		8,212	-	8,212	4,247
<b>Total income</b>		<b>1,358,527</b>	<b>427,000</b>	<b>1,785,527</b>	<b>1,684,829</b>
<b>Expenditure</b>					
Expenditure on raising funds	4	343,993	-	343,993	343,475
Expenditure on charitable activities	5	938,207	166,334	1,104,541	1,214,552
<b>Total expenditure</b>		<b>1,282,200</b>	<b>166,334</b>	<b>1,448,534</b>	<b>1,558,027</b>
<b>Net income and net movement in funds for the year</b>		<b>76,327</b>	<b>260,666</b>	<b>336,993</b>	<b>126,802</b>
Total funds at 1 April 2015		1,333,892	253,334	1,587,226	1,460,424
<b>Total funds at 31 March 2016</b>	<b>15</b>	<b>1,410,219</b>	<b>514,000</b>	<b>1,924,219</b>	<b>1,587,226</b>

The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities.

## Balance Sheet as at 31 March 2016

	Notes	2016		2015	
		£	£	£	£
<b>Fixed Assets</b>					
Tangible assets	9		1		1
Investment	10		-		1
			1		2
<b>Current assets</b>					
Debtors	11	624,734		321,915	
Cash and short term deposits		2,439,165		2,608,746	
		3,063,899		2,930,661	
<b>Liabilities</b>					
Creditors: amounts falling due within one year	12	1,139,681		1,343,437	
<b>Net current assets</b>			1,924,218		1,587,224
<b>Net Assets</b>			1,924,219		1,587,226
<b>Represented by:</b>					
Unrestricted funds	15(i)				
General fund			200,219		123,892
Designated funds			1,210,000		1,210,000
			1,410,219		1,333,892
Restricted funds	15(ii)		514,000		253,334
			1,924,219		1,587,226

Approved by the Board of Directors and authorised for issue on 5 September 2016.

Allyson Kaye MBE

Chair of the Board

Company Registration No. 5403443

## Statement of Cash Flows for year ending 31 March 2016

	Notes	2016	2015
		£	£
<b>Cash flows from operating activities</b>			
Cash flows (used in) / provided by operating activities	18	(177,793)	209,859
<b>Cash flows from investing activities</b>			
Interest received		8,212	4,247
<b>Net cash provided by investing activities</b>		8,212	4,247
<b>Net (decrease)/increase in cash and cash equivalents in the financial year</b>		(169,581)	214,106
<b>Cash and cash equivalents at the beginning of the financial year</b>		2,608,746	2,394,640
<b>Cash and cash equivalents at the end of the financial year</b>		2,439,165	2,608,746

# Notes to the Financial Statements for the year ended 31 March 2016

## 1. Accounting policies

**The principal accounting policies adopted and judgements in the preparation of the financial statements are as follows:**

### 1.1 Basis of accounting

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2016.

The Charitable company meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes.

The charity transitioned from previous UK GAAP to FRS 102 as at 1 April 2014. There was no transitional adjustment.

In preparing the financial statements, the Directors have considered whether in applying the accounting policies required by FRS 102 and the Charities SORP FRS 102, the restatement of comparative items was required. No restatements were required.

The Directors consider that there are no material uncertainties about the charitable company's ability to continue as a going concern.

### 1.2 Income

It is probable that the income will be received and the amount of income receivable can be measured reliably.

Donations are recognised when the charity has entitlement to the funds and it is probable that the income will be received and the amount can be measured reliably.

Donations from fundraising ventures are shown gross, with the associated costs included in fundraising costs. Other income is accounted for on a receivable basis.

Income from government and other grants is recognised when the charity has entitlement to the funds, and performance conditions attached to the grants have been met, it is probable that the income will be received and the amount can be measured reliably and is not deferred.

Legacies are recognised as the earlier of the date on which either the charity is aware that probate has been granted, the estate has been finalised and notification has been made by the executors to the charity that a distribution will be made or when a distribution is received from the estate. Receipt of a legacy, in whole or in part, is only considered probable when the amount can be measured reliably and the charity has been notified of the executor's intention to make a distribution.

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest paid or payable by the Bank.

## 1. Accounting policies (cont)

### 1.3 Fund accounting

The following funds are held by the charity:

- unrestricted general funds - these are funds which can be used in accordance with the charitable objects at the discretion of the Board of Directors.
- designated funds - these are funds set aside by the Board of Directors out of unrestricted general funds for specific future purposes or projects.
- restricted funds - these are funds that can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

### 1.4 Expenditure and irrecoverable VAT

Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably. Expenditure is classified under the following activity headings:

- Costs of raising funds comprise the costs associated with attracting voluntary income and the costs associated with fundraising purposes.
- Expenditure on charitable activities comprises those costs incurred by the charity in the delivery of its activities and services. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support it.
- Grants payable are payments made to third parties in the furtherance of the charitable objects of the charity. In the case of an unconditional grant offer this is accrued once the recipient has been notified of the grant award. The notification gives the recipient a

reasonable expectation that they will receive the one year or multi-year grant. Grant awards that are subject to the recipient fulfilling performance conditions are only accrued when the recipient has been notified of the grant and any remaining unfulfilled condition attaching to that grant is outside of the control of the Directors.

Value added tax is not recoverable and as such is included in the relevant costs in the Statement of Financial Activities.

### 1.5 Costs allocation

Costs are allocated between the expenditure categories of the Statement of Financial Activities on a basis designed to reflect the use of the resource. Costs other than support costs relating to a particular activity are allocated directly. Support costs (staff costs) are allocated to the expense categories according to the role of the individual; the apportionment is disclosed in note 6.

Governance costs comprise all costs involving public accountability of the charity and its compliance with regulation and good practice. These costs include costs related to statutory audit and an apportionment of staff costs. Governance costs are allocated in proportion to expenditure on raising funds and expenditure on charitable activities.

### 1.6 Operating leases

Rentals payable under operating leases are charged to the Statement of Financial Activities as incurred.

### 1.7 Tangible fixed assets

Tangible fixed assets are stated at cost less accumulated depreciation. Depreciation is provided on a straight line basis at the following annual rates in order to write off each asset over its estimated useful life:

Office equipment	20%
------------------	-----

## 1. Accounting policies (cont)

### 1.8 Investments

Fixed asset investments are stated at cost less impairment.

### 1.9 Debtors

Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

### 1.10 Cash at bank and in hand

Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity from the date of opening the deposit.

### 1.11 Creditors

Creditors are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably.

### 1.12 Financial instruments

The charity only has financial assets and liabilities of a kind that qualify as basic financial instruments which include trade and other receivables, trade and other payables and cash and bank balances. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value.

### 1.13 Pensions

Employees of the charity are entitled to join a defined contribution 'money purchase' scheme unless they have exercised their right to opt out of the scheme membership. The money purchase plan is managed by The People's Pension and the plan invests contributions made by the employee and employer in an investment fund to build up over the term of the plan. The pension fund is then converted into a pension upon the

employee's normal retirement age which is defined as when they are eligible for a state pension. The charity has no liability beyond making its contributions and paying across the deductions for the employee's contributions.

### 1.14 Foreign currency translation

Monetary assets and liabilities denominated in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are recorded at the average rate for the month in which the transaction occurred. All differences are taken to the Statement of Financial Activities.

## 2 Legal status of the charity

The charity is a company limited by guarantee and has no share capital. In the event of the charity being wound up, the liability in respect of the guarantee is limited to £10 per member of the charity

### 3. Donations and legacies

	£ General	£ Restricted	2016 £ Total	2015 £ Total
Charitable trusts	55,950	117,000	172,950	365,274
Third party fundraising	104,468	-	104,468	113,776
Legacies	206,829	-	206,829	160,866
In memoriam	143,486	-	143,486	154,805
Challenge and running events	579,108	-	579,108	604,362
Other donations	260,474	310,000	570,474	281,499
	1,350,315	427,000	1,777,315	1,680,582

Income from donations and legacies was £1,777,315 (2015 - £1,680,582) of which £1,350,315 (2015 - £1,307,621) was unrestricted and £427,000 (2015 - £372,961) was restricted. A government grant for £300,000 is included in restricted donations (see note 17).

### 4. Expenditure on raising funds

	2016 £	2015 £
Staff costs	211,069	214,964
Challenge and running events	72,444	85,086
Other	45,883	32,428
	329,396	332,478
Governance costs (see note 7)	14,597	10,997
	343,993	343,475

## 5. Charitable Activities

	Direct £	Support costs £	Total 2016 £	Total 2015 £
<b>Grants payable</b>				
Ovarian Cancer Action Research Centre				
Imperial College/Hammersmith Hospital	710,000	-	710,000	527,364
Research grants underspend	(54,066)	-	(54,066)	(285,571)
	655,934	-	655,934	241,793
University of Oxford	-	-	-	400,000
	655,934	-	655,934	641,793
<b>Other Charitable Activities</b>				
Research Management & Admin:				
Staff costs	-	45,629	45,629	46,129
Research Management	17,751	-	17,751	649
Awareness Activities	233,755	75,910	309,665	456,476
Giving a Voice Activities	933	27,759	28,692	30,617
	908,373	149,298	1,057,671	1,175,664
Governance costs (see note 7)	40,254	6,616	46,870	38,888
	948,627	155,914	1,104,541	1,214,552

A further £200,000 (2015 - £200,000) grant is payable subject to adherence with the conditions and obligations in the original grant application.

Expenditure on charitable activities was £1,104,541 (2015 - £1,214,552) of which £938,207 (2015 - £816,352) was unrestricted and £166,334 (2015 - £398,200) was restricted

	Total 2016 £	Total 2015 £
<b>Reconciliation of grants payable</b>		
Commitments at 1 April 2015	1,187,073	1,229,591
Commitments made in the year	710,000	927,364
Research grants underspend	(54,066)	(285,571)
Grants paid during the year	(809,670)	(684,311)
Commitments at 31 March 2016 and 31 March 2015 are payable within one year (note 12).	1,033,337	1,187,073

## 6. Support Costs Allocation

	2016 £	2016 Number of staff	2015 £	2015 Number of staff
Staff costs including recruitment				
Costs of Generating Funds	211,069	7	214,964	7
Charitable Activities	149,298	4	151,102	4
Governance	42,567	1	39,485	1
	402,934	12	405,551	12

## 7. Governance costs

	2016 £	2015 £
Staff costs	42,567	39,485
Auditor's fees	11,000	7,800
Auditor's other fees - accountancy	7,900	2,600
	61,467	49,885

## 8. Directors and employee information

No Director received any remuneration from the Charity (2015 - Nil). No member of staff was paid over £60,000 (2015 - Nil). One director was reimbursed £165 for general expenses (2015 - £234 for travelling and subsistence expenses).

The average full time equivalent number of persons employed by the Charity during the year was 12 (2015 - 12).

	2016 £	2015 £
Amounts paid to employees of the Charity during the year:		
Salaries and wages	364,590	370,036
Pension costs	4,436	2,760
Social security costs	33,908	32,755
	402,934	405,551

The Charity considers its key management personnel comprise the Directors, the Chief Executive Officer and the senior management team including the Public Affairs and Operation Manager, Senior Fundraising Manager, Research Fundraising Manager and Head of Communications. The total employee benefits of the key management personnel were £202,481 (2015 - £187,887).

## 9. Tangible fixed Assets

	<b>Office equipment</b>
<b>Cost</b>	£
At 1 April 2015 and at 31 March 2016	34,206
<b>Depreciation</b>	
At 1 April 2015 and at 31 March 2016	34,205
<b>Net book values</b>	
At 31 March 2016	1
At 31 March 2015	1

## 10. Fixed Asset Investment

	<b>Shares in subsidiary undertaking</b>
<b>Cost</b>	£
At 1 April 2015	1
Impairment	(1)
At 31 March 2016	-

The charity owned the entire issued share capital of Ovarian Cancer Action Trading Limited. The company had not traded since incorporation and was dissolved on 12 January 2016.

## 11. Debtors

	<b>2016</b>	<b>2015</b>
	£	£
Accrued income	603,781	309,719
Prepayments	20,953	12,196
	624,734	321,915

Accrued income includes amounts totalling £30,000 (2015 - £100,000) receivable after more than one year

## 12. Creditors

	<b>2016</b>	<b>2015</b>
	£	£
<b>amounts falling due within one year</b>		
Trade creditors	67,061	120,222
Social security and other taxes	10,974	8,519
Grants not yet paid	1,033,337	1,187,073
Accruals	28,309	27,623
	1,139,681	1,343,437

### 13. Financial Commitments

At 31 March 2016 the charity was committed to making the following payments under a non-cancellable operating lease in respect of land and buildings as follows:

	2016 £	2015 £
Operating lease which expires:		
Within one year	60,600	18,227
Between 2 and 5 years	57,944	-
	118,544	18,227

### 14. Pension Costs

The charity contributes to a defined contribution pension scheme. The assets of the scheme are held separately from those of the charity in independently administered funds. The pension cost charge representing contributions payable by the charity to the funds amounted to £4,436 (2015 - £2,760). As at 31 March 2016, £13,034 (2015 - £13,034) remained unpaid.

### 15. Funds

#### (i) Unrestricted funds

	General fund £	Designated fund £	Total £	2015 £
At 1 April 2015	123,892	1,210,000	1,333,892	1,194,601
Net income for year	76,327	-	76,327	139,291
At 31 March 2016	200,219	1,210,000	1,410,219	1,333,892

Designated funds are in respect of planned research work.

#### (ii) Restricted funds

		Movements in Funds			
		As at 1.4.2015 £	Incoming £	Outgoing £	As at 31.3.2016 £
Restricted funds					
Ovarian Cancer Research					
Research Centre, Imperial College		53,334	73,000	(126,334)	-
BriTROC		-	10,000	(10,000)	-
University of Oxford		200,000	30,000	(30,000)	200,000
Regional Awareness		-	14,000	-	14,000
Tampon Tax Fund	Note 17	-	300,000	-	300,000
		253,334	427,000	(166,334)	514,000

## 16. Analysis of net assets between funds

	Restricted	Unrestricted Funds		Total
	£	General £	Designated £	£
Fixed assets	-	1	-	1
Current assets less liabilities	514,000	200,218	1,210,000	1,924,218
	514,000	200,219	1,210,000	1,924,219

## 17. Government Grants

A donation of £300,000 was granted from the Department of Health to fund the Charity's cancer prevention strategy to reduce the number of ovarian deaths by 17%, saving up to 1,000 women's lives a year in the UK. This will be done through a genetic screening by researchers at the Ovarian Cancer Action Research Centre and through public awareness raising carried out by a new Cancer Prevention Officer role at the Charity.

## 18. Cash generated from operations

	2016 £	2015 £
Net Movement in Funds for the Year	336,993	126,802
<b>Adjustments for:</b>		
Impairment and depreciation of fixed assets	1	6,841
Interest income	(8,212)	(4,247)
<b>Movements in working capital:</b>		
(Increase)/Decrease in debtors	(302,819)	75,148
(Decrease)/Increase in creditors	(203,756)	5,315
<b>Cash flows (used in) / provided by operating activities</b>	<b>(177,793)</b>	<b>209,859</b>

## 19. Related party transactions

There have been no related party transactions in the year ended 31 March 2016 or in the year ended 31 March 2015.

# The year in photos



# Thank yous

**We couldn't do what we do without you - our supporters, donors, volunteers - the list is endless. Your support makes everything we do possible. We'd like to say a special thank you to the following who went above and beyond for us this year.**

Action for Charity for all their help organising the so successful Women V Cancer events.

AEL Partnerships

Edward Azouz and AR&V Group

Betty Messenger Charitable Foundation

The OCA Board of Trustees, in particular Chair Allyson Kaye

Boxercise UK Ltd

Doris Field Charitable Trust

Tony Eisen and the Lexus Foundation

First Women Awards who selected us for the second year running as their beneficiary charity.

Professor Fran Balkwin and Professor David Bowtell

The George John & Shelah Livanos Charitable Trust

The Greendale Foundation

Patron Gwyneth Strong and her husband Jesse Birdsall for winning TV 'Celebrity Mr and Mrs' for us

The Hugh Fraser Foundation

HM Treasury for making us a beneficiary of the Tampon Tax

Isle of Man Anti-Cancer Association

The Estate of the late Lady Gillian Boughey

Natracare

Paperchase for continuing to support us through Mother's Day card sales

Raffinger Stuart Chartered Accountants

Rosetrees Trust

All our amazing contributors to Her Recipes for Life

Roche

Our Scientific Advisory Board

Spirit of Christmas Fair for picking us as their beneficiary charity

Rob, Oliver, and Toby Coan

Alan Mold and family

Darren Hand and family

Ed King

Adam Davey

Alisdair Thornton

Our Tribute Fund holders

The OCA Voices

Patron Gwyneth Strong

HM Treasury

Paperchase

Everyone who 'Walked in Her Name' around the country

Everyone who kindly gave a gift to Ovarian Cancer Action in their will.

Our wonderful volunteers, Bob Bowyer, Salman Mahmood and Lukia Lubega



**Thank you so much to our incredible supporters who have run marathons, cycled to Paris, abseiled down cliffs, trekked up Kilimanjaro, walked from coast to coast and so much more to raise money for OCA. Together you covered 9,300 miles and raised £579,108 - WOW!**

# The legal bit

## Ovarian Cancer Action

A company limited by guarantee  
Registered in England and Wales 5403443  
Registered charity number 1109743  
(England and Wales)  
Registered charity number SC 043478 (Scotland)

## Registered office

8-12 Camden High Street  
London NW1 0JH  
Telephone: 020 7380 1730  
Website: [www.ovarian.org.uk](http://www.ovarian.org.uk)  
Email: [info@ovarian.org.uk](mailto:info@ovarian.org.uk)  
Twitter: @OvarianCancerUK

## Directors

Allyson Kaye MBE (Chair)  
Nathalie Burdet (appointed on 19.2.16)  
Daniel Harris (resigned on 22.6.16)  
John Harris CBE  
Jenny Knott  
Martin Paisner CBE  
Dr Wayne Phillips (appointed on 7.12.15)  
Emma Scott  
Lord Turnberg  
Professor Sir Nick Wright

## Honorary Patrons

The Hon. Nigel Havers  
Lord Jones of Birmingham  
Dr Chris Steele MBE  
Gwyneth Strong

## Honorary President of Ovarian Cancer Action

Dr. Robert C. Bast Jr

## Auditors

Wilson Wright LLP  
Chartered Accountants  
Thavies Inn House  
3-4 Holborn Circus  
London EC1N 2HA

## Legal Advisors

Squire Patton Boggs (UK) LLP  
7 Devonshire Square  
London EC2M 4YH

## Accountant and Honorary Treasurer

Nicholas Kaye, FCA  
AEL Partners LLP  
201 Haverstock Hill  
London NW3 4QG

## Bankers

National Westminster Bank PLC  
1-4 Berkeley Square House  
Berkeley Square  
London W1A 1SN

Coutts & Co  
440 Strand  
London WC2R 0QS

## Staff

Kim Broodie, Finance Officer  
Jessica Champion, Head of Communications  
Nick Healey, Research Fundraising Manager  
Ross Little, Healthcare Projects Manager  
Emily Legg, Senior Fundraising Manager  
Amelia Meldau, Challenge Events Manager  
Beatrix Passmore, Community Fundraiser and Supporter Care Coordinator  
Marie-Claire Platt, Public Affairs and Operations Manager  
Alicia Roberts, Wales Regional Officer  
Jennifer Schembri, Digital Manager  
Katherine Taylor, Chief Executive  
Hannah Woolcott, Fundraising Team Assistant

## Consultant

Gilda Witte

## Scientific Advisory Board

Dr Robert C. Bast Jr (President)  
Dr Jonathan Berek  
Dr Michael Bookman  
Professor Hilary Calvert  
Professor Ian Hart  
Professor Kenneth Nephew  
Dr Mike Seiden  
Dr Anil Sood

## Recipients of grants

Professor Hani Gabra (Director) - Ovarian Cancer Action Research Centre  
Professor Iain McNeish and Dr James Brenton - The British Translational Research Ovarian Cancer Collaborative (BriTROC)  
Professor Ahmed Ahmed, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital

## Ovarian Cancer Action

8-12 Camden High Street  
London  
NW1 0JH

Telephone: 020 7380 1730

Website: [www.ovarian.org.uk](http://www.ovarian.org.uk)

Email: [info@ovarian.org.uk](mailto:info@ovarian.org.uk)

Twitter: @OvarianCancerUK




Monica




Erica




Rita



Tina




Sandra




Mary



Jessica



Ore



Daisy



Vicke




Leonie



Rebecca



Niralee



Jess



Lynsey



Steph




Kat



Maryna



Becky



Malika